XNCR News and Press, Xencor Inc. From 05/23/19

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business developm...

Thinly traded Xencor ( XNCR +5.2% ) is up on 20% higher volume, albeit on turnover of only 269K shares, following its Q1 report released after the close yesterday. More news on: Xencor, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Xencor, Inc. (XNCR) Q1 2019 Earnings Conference Call May 09, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director & Head of Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer Paul Foster - Senior Vice ...

Xencor (NASDAQ: XNCR ): Q1 GAAP EPS of $1.38 beats by $1.79 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Management to Host Conference Call at 4:30 p.m. ET today -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial res...

— XmAb23104, a PD-1 x ICOS bispecific antibody, is the sixth XmAb ® antibody engineered with Xencor’s bispecific Fc domain to enter clinical development — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoc...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold ...

-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing ...

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year tests of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio...